Amarin is a clinical-stage biopharmaceutical company with a focus on cardiovascular disease. The Company’s lead product candidate is AMR101, a prescription grade Omega-3 product comprising not less than 96% ultra-pure ethyl eicosapentaenoic acid (EPA), which is entering Phase 3 clinical trials for the treatment of hypertriglyceridemia and mixed dyslipidemia. Amarin also has next-generation lipid candidates under evaluation for preclinical development. Amarin recently established its research and development headquarters in Mystic, Connecticut with an experienced research and development team. Amarin’s programs capitalize on its lipid science expertise and the known therapeutic benefits of Omega-3 products in treating cardiovascular disease. Amarin has a number of non-core programs for partnering in the area of central nervous system (CNS) disorders, including Huntington’s disease, myasthenia gravis and Parkinson’s disease.
Company Growth (employees)
Dublin, IE
Size (employees)
210 (est)
Amarin was founded in 1991 and is headquartered in Dublin, IE

Key People at Amarin

Colin Stewart

Colin Stewart

President and CEO
Joseph S. Zakrzewski

Joseph S. Zakrzewski

Executive Chairman and Chief Executive Officer
John Thero

John Thero

Declan Doogan

Declan Doogan

Chief Medical Officer

Amarin Office Locations

Amarin has offices in Dublin and Bedminster Township
Dublin, IE (HQ)
Pembroke House Pembroke Street Upper
Bedminster Township, US
1430 Us 206

Amarin Data and Metrics

Amarin Financial Metrics

Amarin's revenue was reported to be $130.1 m in FY, 2016 which is a 59% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

130.1 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

95.7 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(86.4 m)

EBIT (FY, 2016)

(65.6 m)

Market capitalization (22-Jun-2017)

896 m

Closing share price (22-Jun-2017)


Cash (31-Dec-2016)

98.3 m
Amarin's current market capitalization is $896 m.
FY, 2013FY, 2014FY, 2015FY, 2016


26.4 m54.2 m81.8 m130.1 m

Revenue growth, %


Cost of goods sold

11.9 m20.5 m27.9 m34.4 m

Gross profit

14.4 m33.7 m53.9 m95.7 m

Gross profit Margin, %


R&D expense

72.8 m50.3 m51.1 m50 m

General and administrative expense

123.8 m79.3 m101 m111.4 m

Operating expense total

208.5 m129.7 m152.1 m161.3 m


(182.1 m)(96 m)(98.2 m)(65.6 m)

EBIT margin, %


Interest expense

34.2 m18.6 m20.2 m18.7 m

Interest income

343 k96 k132 k234 k

Pre tax profit

(169.4 m)(59.2 m)(118.3 m)(76.4 m)

Income tax expense

3.2 m2.8 m3.1 m(10 m)

Net Income

(166.2 m)(56.4 m)(115.2 m)(86.4 m)
FY, 2013FY, 2014FY, 2015FY, 2016


191.5 m119.5 m107 m98.3 m

Accounts Receivable

3.6 m7.8 m13.8 m20 m


19 m20.5 m

Current Assets

219.4 m145.3 m143.5 m146.3 m


579 k381 k243 k78 k

Total Assets

252.5 m171.1 m173.5 m167 m

Accounts Payable

6.4 m8.5 m10.8 m6.1 m

Total Debt

105 m106.3 m

Current Liabilities

37.5 m40.3 m50.7 m76.2 m

Additional Paid-in Capital

738.8 m738.9 m816.2 m964.9 m

Retained Earnings

(913.9 m)(970.2 m)(1.1 b)(1.2 b)

Total Equity

(33.9 m)(88.4 m)(129.2 m)(9.1 m)

Debt to Equity Ratio

-1.2 x-0.8 x

Debt to Assets Ratio

0.6 x0.6 x

Financial Leverage

-7.5 x-1.9 x-1.3 x-18.4 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(166.2 m)(56.4 m)(115.2 m)(86.4 m)

Depreciation and Amortization

246 k198 k166 k138 k

Accounts Receivable

(3.6 m)(4.2 m)(6 m)(6.2 m)


(5.4 m)13 m(5.3 m)(1.5 m)

Accounts Payable

10.5 m2.4 m(652 k)(6.2 m)

Cash From Operating Activities

(190.3 m)(72.3 m)(84.7 m)(71.8 m)

Cash From Investing Activities

(14 k)(14 k)(28 k)(21 k)

Cash From Financing Activities

121.6 m334 k72.2 m63.1 m

Interest Paid

6.1 m10 m12.6 m17.1 m

Income Taxes Paid

1.4 m781 k711 k1.5 m
Y, 2016

Financial Leverage

-18.4 x

Amarin Market Value History

Amarin Company Life and Culture

You may also be interested in